WHO Global Tuberculosis Report 2026 Highlights Progress Amid Funding Challenges

The World Health Organization (WHO) Global Tuberculosis Report 2026 indicates continued global progress in reducing tuberculosis (TB) cases and deaths. Domestic funding for TB increased by 14% to US$ 5.6 billion between 2024 and 2025, helping to offset declines in international financing. Despite these efforts, an estimated 10.6 million people developed TB and 1.1 million died from the disease in 2025. The world reached the first mortality milestone of WHO's End TB Strategy, albeit five years later than planned. Drug-resistant TB remains a significant public health challenge, with only 42% of estimated cases receiving treatment in 2025. The report also notes a critical insufficiency in TB research investment, which stood at US$ 1.2 billion in 2023, far below the US$ 5 billion annual target for 2027.

Context

Tuberculosis remains a leading cause of death worldwide, with millions affected each year. The WHO's End TB Strategy aims to reduce mortality and incidence rates, but progress has been slower than anticipated. The increase in domestic funding is a positive sign, yet it is overshadowed by a decline in international support and insufficient research investment.

Why it matters

The WHO Global Tuberculosis Report 2026 highlights ongoing progress in combating tuberculosis, a major global health issue. Despite increased domestic funding, significant challenges remain, particularly with drug-resistant strains of the disease. Understanding these dynamics is crucial for public health strategies and resource allocation.

Implications

The findings of the report may influence policy decisions regarding health funding and research priorities. Countries with high TB burdens could face intensified pressure to improve treatment and prevention strategies. The ongoing challenges with drug-resistant TB could have significant implications for public health systems and global health security.

What to watch

In the near term, stakeholders will be monitoring funding trends and the effectiveness of domestic initiatives to combat TB. The response to drug-resistant TB cases will also be critical, as public health officials seek to improve treatment rates. Additionally, upcoming global health conferences may address the funding gap for TB research.